초록 ▼

An upconversion nanoparticle includes at least one host selected from LiYF4, NaY, NaYF4, NaGdF4, and CaF3, at least one sensitizer selected from Sm3+, Nd3+, Dy3+, Ho3+, and Yb3+ doped in the at least one host, and at least one activator selected from Er3+, Ho3+, Tm3+, and Eu3+ doped in the at least

An upconversion nanoparticle includes at least one host selected from LiYF4, NaY, NaYF4, NaGdF4, and CaF3, at least one sensitizer selected from Sm3+, Nd3+, Dy3+, Ho3+, and Yb3+ doped in the at least one host, and at least one activator selected from Er3+, Ho3+, Tm3+, and Eu3+ doped in the at least one host. The upconversion nanoparticle is designed using a calculation from first principles to absorb light in the near-infrared wavelength range whose stability is ensured. Further, a hyaluronic acid-upconversion nanoparticle conjugate, in which the upconversion nanoparticle as described above is bonded to hyaluronic acid, is provided to be used in various internal sites with a hyaluronic acid receptor, particularly enables targeting, and increases an internal retention period and biocompatibility thereof.

대표청구항 ▼

1. An upconversion nanoparticle, comprising: at least one host selected from LiYF4, NaY, NaYF4, NaGdF4, and CaF3;at least one sensitizer selected from Sm3+, Nd3+, Dy3+, Ho3+, and Yb3+ doped in the at least one host; andat least one activator selected from Er3+, Ho3+, Tm3+, and Eu3+ doped in the at l

1. An upconversion nanoparticle, comprising: at least one host selected from LiYF4, NaY, NaYF4, NaGdF4, and CaF3;at least one sensitizer selected from Sm3+, Nd3+, Dy3+, Ho3+, and Yb3+ doped in the at least one host; andat least one activator selected from Er3+, Ho3+, Tm3+, and Eu3+ doped in the at least one host. 2. The upconversion nanoparticle of claim 1, determined by calculating an optimal chemical composition of a lanthanide-based ion-doped upconversion nanoparticle absorbing light having at least one wavelength among wavelengths of 808 nm, 980 nm, and 1,064 nm, using a calculation from first principles. 3. The upconversion nanoparticle of claim 1, configured to absorb light having at least one wavelength among wavelengths of 808 nm, 980 nm, and 1,064 nm to emit visible light. 4. The upconversion nanoparticle of claim 1, wherein a mole ratio of the at least one sensitizer to the at least one host is 80:10 to 80:60. 5. A hyaluronic acid-upconversion nanoparticle conjugate comprising: the upconversion nanoparticle according to claim 1; and hyaluronic acid or a derivative of hyaluronic acid bonded to the upconversion nanoparticle. 6. The hyaluronic acid-upconversion nanoparticle conjugate of claim 5, further comprising: a photosensitizer. 7. The hyaluronic acid-upconversion nanoparticle conjugate of claim 6, wherein the photosensitizer is at least one selected from chlorine e6 (Ce6), a porphyrin-based photosensitizer, and a non-porphyrin-based photosensitizer. 8. The hyaluronic acid-upconversion nanoparticle conjugate of claim 7, wherein 1 to 3 parts by weight of the photosensitizer is bonded to 1 part by weight of the upconversion nanoparticle. 9. The hyaluronic acid-upconversion nanoparticle conjugate of claim 5, wherein the derivative of hyaluronic acid is hyaluronic acid substituted with cystamine, having a structure represented by the following Chemical Formula 1, where x and y are integers selected from 16 to 2,500, respectively. 10. The hyaluronic acid-upconversion nanoparticle conjugate of claim 9, wherein the cystamine is substituted at a replacement ratio of 10% to 21% with respect to the hyaluronic acid. 11. The hyaluronic acid-upconversion nanoparticle conjugate of claim 5, wherein a weight ratio of the upconversion nanoparticle to the hyaluronic acid or the derivative of hyaluronic acid is 1:1 to 4:1. 12. A method of producing an upconversion nanoparticle, the method comprising: (a) producing a solution by mixing a host precursor, a sensitizer, an activator, and a solvent; and(b) producing an upconversion nanoparticle by subjecting the solution to a heat treatment. 13. The method of claim 12, wherein the host precursor comprises at least one selected from YCl3.H2O, YbCl3.H2O, SmCl3.H2O, NdCl3.H2O, GdCl3.H2O, Ca(CF3COO)2, CF3COONa, Y(CF3COO)3, Yb(CF3COO)3, Gd(CF3COO)3, Sm(CF3COO)3, Nd(CF3COO)3, NH4F, and NaOH. 14. The method of claim 13, wherein the solvent comprises octadecene-1. 15. The method of claim 14, wherein the solution further comprises at least one selected from oleic acid and oleylamine. 16. The method of claim 12, wherein the heat treatment is conducted at 250° C. to 400° C. 17. A method of producing a hyaluronic acid-upconversion nanoparticle conjugate, the method comprising: (a) bonding the upconversion nanoparticle produced according to claim 12 to hyaluronic acid or a derivative of hyaluronic acid. 18. The method of claim 17, wherein the bonding comprises (a′) mixing or dissolving the hyaluronic acid or the derivative of hyaluronic acid with the upconversion nanoparticle, and then adding, as a catalyst, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) to a mixture or a solution, so as to react the mixture or the solution with the EDC. 19. The method of claim 18, further comprising: (a-1) modifying a surface of the upconversion nanoparticle, prior to operation (a′). 20. The method of claim 19, wherein the surface of the upconversion nanoparticle is modified using at least one selected from polyallylamine, polymethylmethacrylate (PMMA), 3-aminopropyltriethoxysilane (APTES), tetraethyl orthosilicate (TEOS), 3,4-dihydroxyphenylalanine (DOPA), and cetyltrimethylammoniumbromide (CTAB). 21. A composition for optogenetics applicable to optogenetics, the composition for optogenetics comprising: the hyaluronic acid-upconversion nanoparticle conjugate according to claim 5 as an active ingredient. 22. The composition for optogenetics of claim 21, configured to be used to control nerve cells, using a laser beam having at least one wavelength among wavelengths of 808 nm, 980 nm, and 1,064 nm. 23. A composition for photodynamic therapy, comprising: the hyaluronic acid-upconversion nanoparticle conjugate according to claim 5 as an active ingredient. 24. The composition for photodynamic therapy of claim 23, configured to be used in the treatment of skin diseases or cancers. 25. The composition for photodynamic therapy of claim 24, configured as a patch preparation, a depot preparation, or an external preparation. 26. A non-invasive internal light source delivery system, configured to use transdermal delivery of the hyaluronic acid-upconversion nanoparticle conjugate according to claim 5. 27. The non-invasive internal light source delivery system of claim 26, configured to be used in the treatment and diagnosis of cancers, skin diseases, or eye diseases. 28. The non-invasive internal light source delivery system of claim 27, configured to be used in fluorescent tattoos. 29. The non-invasive internal light source delivery system of claim 28, configured to be applicable to cell therapy, using a hydrogel produced through a physical host-guest reaction between a hyaluronic acid-cucurbituril conjugate, in which cucurbituril [6] is bonded to hyaluronic acid substituted with cystamine, and/or a Ce6-hyaluronic acid-cucurbituril conjugate, in which Ce6 as a photosensitizer is additionally bonded to the hyaluronic acid-cucurbituril conjugate, and a hyaluronic acid-upconversion nanoparticle conjugate.